Research programme: Fc receptor modulators - Takeda
Alternative Names: Anti-Fc gamma RIIb antibody - Takeda; Anti-FcƴRIIb IgE; Anti-FcƴRIIb IgG; Anti-FcγRIIb antibody - Takeda; Autoimmune disease therapy - Takeda; sFcR - ShireLatest Information Update: 15 Jan 2019
At a glance
- Originator SuppreMol
- Developer Shire
- Class Monoclonal antibodies
- Mechanism of Action Fc gamma receptor IIB modulators; Fc receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Hypersensitivity
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 28 Apr 2018 No recent reports of development identified for research development in Allergy in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (Parenteral)